MediciNova completes last patient visit in double-blind Phase 2b/3 COMBAT-ALS trial of MN166
AI Market Summary
MediciNova reported last patient's last visit completion for the double-blind phase of its Phase 2b/3 COMBAT-ALS trial of MN166 (ibudilast), marking the end of blinded data collection ahead of planned topline results by end-2026. While this is a positive operational milestone, efficacy outcomes remain unknown, limiting immediate read-through to broader markets. Any near-term impact is likely confined to single-name biotech risk sentiment.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.50%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
MediciNova said it has completed the last patient’s final visit in the double-blind portion of COMBAT-ALS, its Phase 2b/3 trial of MN-166 (ibudilast) for amyotrophic lateral sclerosis. The study randomized 234 participants, and data collection for the double-blind phase has now finished, though efficacy results have not been released. The company’s shares are listed on Nasdaq and the Tokyo Stock Exchange.
